Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches

Natália    F.F.   Pirolla; Victor    S.    Batista; Flávia    Pereira    Dias Viegas; Vanessa    Silva    Gontijo; Caitlin    R.    McCarthy; Claudio       Viegas; Nailton    M.    Nascimento-Júnior
Abstract

We describe herein the therapeutic targets involved in Alzheimer’s disease as well as the available drugs and their synthetic routes. Bioactive compounds under development are also exploited to illustrate some recent research advances on the medicinal chemistry of Alzheimer’s disease, including structure-activity relationships for some targets. The importance of multi-target approaches, including some examples from our research projects, guides new perspectives in search of more effective drug candidates. This review comprises the period between 2001 and early 2020.
Keywords: Alzheimer's disease, structure-activity relationship, multi-target-directed ligands, acetylcholinesterase, nicotinic acetylcholine receptors, synthetic routes.
Graphical Abstract

[1] 
Hippius H, Neundörfer G. The discovery of Alzheimer’s disease. Dialogues Clin Neurosci  2003; 5(1): 101-8.
[PMID:  22034141] 
[2] 
Dineley KT, Pandya AA, Yakel JL. Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci  2015; 36(2): 96-108.
[http://dx.doi.org/10.1016/j.tips.2014.12.002] [PMID:  25639674] 
[3] 
Cheng Q, Yakel JL. The effect of α7 nicotinic receptor activation on glutamatergic transmission in the hippocampus. Biochem Pharmacol  2015; 97(4): 439-44.
[http://dx.doi.org/10.1016/j.bcp.2015.07.015] [PMID:  26212541] 
[4] 
Galvez B, Gross N, Sumikawa K. Activation of α7 nicotinic acetylcholine receptors protects potentiated synapses from depotentiation during theta pattern stimulation in the hippocampal CA1 region of rats. Neuropharmacology  2016; 105: 378-87.
[http://dx.doi.org/10.1016/j.neuropharm.2016.02.008] [PMID:  26867505] 
[5] 
Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet  2010; 19(R1): R12-20.
[http://dx.doi.org/10.1093/hmg/ddq160] [PMID:  20413653] 
[6] 
Kumar K, Kumar A, Keegan RM, Deshmukh R. Recent advances in the neurobiology and neuropharmacology of Alzheimer’s disease. Biomed Pharmacother  2018; 98: 297-307.
[http://dx.doi.org/10.1016/j.biopha.2017.12.053] [PMID:  29274586] 
[7] 
Juma KK. A current understanding of Alzheimer’s disease and the prospects of phytopharmacological intervention as a management strategy. J Neurol Disord  2015; 3: 1-7.
[8] 
Harris JR, Fahrenholz F. Alzheimer’s disease: Cellular and Molecular Aspects of Amyloid Beta, Subcellular Biochemistry 38.  1st ed. Springer 2005.
[9] 
Cummings JL, Isaacson RS, Schmitt FA, Velting DM. A practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann Clin Transl Neurol  2015; 2(3): 307-23.
[http://dx.doi.org/10.1002/acn3.166] [PMID:  25815358] 
[10] 
Molino I, Colucci L, Fasanaro AM, Traini E, Amenta F. Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer’s disease: a review of clinical trials. ScientificWorldJournal  2013; 2013925702
[http://dx.doi.org/10.1155/2013/925702] [PMID:  24288512] 
[11] 
León R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev  2013; 33(1): 139-89.
[http://dx.doi.org/10.1002/med.20248] [PMID:  21793014] 
[12] 
Viegas FPD, Simões MCR, Rocha MD, Castelli MR, Moreira MS, Viegas-Jr C. Doença de Alzheimer: Caracterização, Evolução e Implicações do Processo Neuroinflamatório. Rev Virtual Quim  2011; 3: 286-306.
[http://dx.doi.org/10.5935/1984-6835.20110034] 
[13] 
Cuny GD. Foreword: neurodegenerative diseases: challenges and opportunities. Future Med Chem  2012; 4(13): 1647-9.
[http://dx.doi.org/10.4155/fmc.12.123] [PMID:  22924500] 
[14] 
Dias KST, Viegas C Jr. Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease. Curr Neuropharmacol  2014; 12(3): 239-55.
[http://dx.doi.org/10.2174/1570159X1203140511153200] [PMID:  24851088] 
[15] 
da Rocha MD, Viegas FPD, Campos HC, et al. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer’s disease. CNS Neurol Disord Drug Targets  2011; 10(2): 251-70.
[http://dx.doi.org/10.2174/187152711794480429] [PMID:  20874701] 
[16] 
Campos HC, da Rocha MD, Viegas FPD, et al. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson’s disease. CNS Neurol Disord Drug Targets  2011; 10(2): 239-50.
[http://dx.doi.org/10.2174/187152711794480483] [PMID:  20874702] 
[17] 
Kumar A, Singh A. Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep  2015; 67(2): 195-203.
[http://dx.doi.org/10.1016/j.pharep.2014.09.004] [PMID:  25712639] 
[18] 
Nesi G, Sestito S, Digiacomo M, Rapposelli S. Oxidative Stress, Mitochondrial Abnormalities and Proteins Deposition: Multitarget Approaches in Alzheimer’s Disease. Curr Top Med Chem  2017; 17(27): 3062-79.
[PMID:  28595557] 
[19] 
Shi S, Wang Z, Qiao Z. The multifunctional anti-inflammatory drugs used in the therapy of Alzheimer’s disease. Curr Med Chem  2013; 20(20): 2583-8.
[http://dx.doi.org/10.2174/0929867311320200006] [PMID:  23590711] 
[20] 
Sanabria-Castro A, Alvarado-Echeverría I, Monge-Bonilla C. Molecular Pathogenesis of Alzheimer’s Disease: An Update. Ann Neurosci  2017; 24(1): 46-54.
[http://dx.doi.org/10.1159/000464422] [PMID:  28588356] 
[21] 
Duce JA, Tsatsanis A, Cater MA, et al. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell  2010; 142(6): 857-67.
[http://dx.doi.org/10.1016/j.cell.2010.08.014] [PMID:  20817278] 
[22] 
Sun XY, Wei YP, Xiong Y, et al. Synaptic released zinc promotes tau hyperphosphorylation by inhibition of protein phosphatase 2A (PP2A). J Biol Chem  2012; 287(14): 11174-82.
[http://dx.doi.org/10.1074/jbc.M111.309070] [PMID:  22334661] 
[23] 
Cristóvão JS, Santos R, Gomes CM. Metals and Neuronal Metal Binding Proteins Implicated in Alzheimer’s Disease. Oxid Med Cell Longev  2016; 20169812178
[http://dx.doi.org/10.1155/2016/9812178] [PMID:  26881049] 
[24] 
Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci  2013; 34(6): 340-6.
[http://dx.doi.org/10.1016/j.tips.2013.04.005] [PMID:  23664668] 
[25] 
Malaguarnera M, Ferri R, Bella R, Alagona G, Carnemolla A, Pennisi G. Homocysteine, vitamin B12 and folate in vascular dementia and in Alzheimer disease. Clin Chem Lab Med  2004; 42(9): 1032-5.
[http://dx.doi.org/10.1515/CCLM.2004.208] [PMID:  15497469] 
[26] 
Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem  2008; 51(3): 347-72.
[http://dx.doi.org/10.1021/jm7009364] [PMID:  18181565] 
[27] 
Liu X, Zhu F, Ma XH, et al. Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery. Curr Med Chem  2013; 20(13): 1646-61.
[http://dx.doi.org/10.2174/0929867311320130005] [PMID:  23410165] 
[28] 
Carreiras MC, Mendes E, Perry MJ, Francisco AP, Marco-Contelles J. The multifactorial nature of Alzheimer’s disease for developing potential therapeutics. Curr Top Med Chem  2013; 13(15): 1745-70.
[http://dx.doi.org/10.2174/15680266113139990135] [PMID:  23931435] 
[29] 
Agis-Torres A, Sölhuber M, Fernandez M, Sanchez-Montero JM. Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease. Curr Neuropharmacol  2014; 12(1): 2-36.
[http://dx.doi.org/10.2174/1570159X113116660047] [PMID:  24533013] 
[30] 
Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol  2013; 11(3): 315-35.
[http://dx.doi.org/10.2174/1570159X11311030006] [PMID:  24179466] 
[31] 
Ferreira-Vieira TH, Guimarães IM, Silva FR, Ribeiro FM. Alzheimer’s disease: Targeting the Cholinergic System. Curr Neuropharmacol  2016; 14(1): 101-15.
[http://dx.doi.org/10.2174/1570159X13666150716165726] [PMID:  26813123] 
[32] 
Acetylcholinesterase TV. Mechanism of Catalysis and Inhibition Curr Med Chem  2001; 1: 155-70.
[33] 
García-Ayllón MS, Small DH, Avila J, Sáez-Valero J. Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloid. Front Mol Neurosci  2011; 4: 22.
[http://dx.doi.org/10.3389/fnmol.2011.00022] [PMID:  21949503] 
[34] 
Nave S, Doody RS, Boada M, et al. Sembragiline in moderate Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase II trial. J Alzheimers Dis  2017; 58(4): 1217-28.
[http://dx.doi.org/10.3233/JAD-161309] [PMID:  28550255] 
[35] 
Rafii MS, Walsh S, Little JT, et al. Alzheimer’s Disease Cooperative Study. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology  2011; 76(16): 1389-94.
[http://dx.doi.org/10.1212/WNL.0b013e318216eb7b] [PMID:  21502597] 
[36] 
Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging ClinicalTrials.gov Identifier: NCT02931136, 2020.
[37] 
Costanzo P, Cariati L, Desiderio D, et al. Design, synthesis and evaluation of donepezil-like compounds as AChE and BACE-1 inhibitors. ACS Med Chem Lett  2016; 7(5): 470-5.
[http://dx.doi.org/10.1021/acsmedchemlett.5b00483] [PMID:  27190595] 
[38] 
Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer’s disease pathology and treatment. Neuropharmacology  2015; 96(Pt B): 255-62.
[http://dx.doi.org/10.1016/j.neuropharm.2014.11.018] [PMID: 25514383] 
[39] 
Sadigh-Eteghad S, Mahmoudi J, Babri S, Talebi M. Effect of alpha-7 nicotinic acetylcholine receptor activation on beta-amyloid induced recognition memory impairment. Possible role of neurovascular function. Acta Cir Bras  2015; 30(11): 736-42.
[http://dx.doi.org/10.1590/S0102-865020150110000003] [PMID:  26647792] 
[40] 
Atzori M, Oscos FG, Arias HR. α7 Nicotinic acetylcholine receptor mediated anti-inflammatory actions modulate brain functions. Neutransmitter  2016; 3: 1-15.
[41] 
Oz M, Lorke DE, Yang KH, Petroianu G. On the interaction of β-amyloid peptides and α7-nicotinic acetylcholine receptors in Alzheimer’s disease. Curr Alzheimer Res  2013; 10(6): 618-30.
[http://dx.doi.org/10.2174/15672050113109990132] [PMID:  23627750] 
[42] 
Wang X, Lippi G, Carlson DM, Berg DK. Activation of α7-containing nicotinic receptors on astrocytes triggers AMPA receptor recruitment to glutamatergic synapses. J Neurochem  2013; 127(5): 632-43.
[http://dx.doi.org/10.1111/jnc.12436] [PMID:  24032433] 
[43] 
Feuerbach D, Pezous N, Weiss M, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Phar  2014; 172: 1292-304.
[http://dx.doi.org/10.1111/bph.13001] 
[44] 
Mazurov AA, Speake JD, Yohannes D. Discovery and development of α7 nicotinic acetylcholine receptor modulators. J Med Chem  2011; 54(23): 7943-61.
[http://dx.doi.org/10.1021/jm2007672] [PMID:  21919481] 
[45] 
Huang M, Felix AR, Flood DG, et al. The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology (Berl)  2014; 231(23): 4541-51.
[http://dx.doi.org/10.1007/s00213-014-3596-0] [PMID:  24810107] 
[46] 
Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci  2020; 27(1): 18.
[http://dx.doi.org/10.1186/s12929-019-0609-7] [PMID:  31906949] 
[47] 
Schrimpf MR, Sippy KB, Briggs CA, et al. SAR of α7 nicotinic receptor agonists derived from tilorone: exploration of a novel nicotinic pharmacophore. Bioorg Med Chem Lett  2012; 22(4): 1633-8.
[http://dx.doi.org/10.1016/j.bmcl.2011.12.126] [PMID:  22281189] 
[48] 
Suresh A, Hung A. Molecular simulation study of the unbinding of α-conotoxin [ϒ4E]GID at the α7 and α4β2 neuronal nicotinic acetylcholine receptors. J Mol Graph Model  2016; 70: 109-21.
[http://dx.doi.org/10.1016/j.jmgm.2016.09.006] [PMID:  27721068] 
[49] 
Wang J, Kuryatov A, Sriram A, et al. An accessory agonist binding site promotes activation of α4β2* nicotinic acetylcholine receptors. J Biol Chem  2015; 290(22): 13907-18.
[http://dx.doi.org/10.1074/jbc.M115.646786] [PMID:  25869137] 
[50] 
Grupe M, Grunnet M, Bastlund JF, Jensen AA. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach. Basic Clin Pharmacol Toxicol  2015; 116(3): 187-200.
[http://dx.doi.org/10.1111/bcpt.12361] [PMID:  25441336] 
[51] 
Grady SR, Salminen O, Laverty DC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol  2007; 74(8): 1235-46.
[http://dx.doi.org/10.1016/j.bcp.2007.07.032] [PMID:  17825262] 
[52] 
Brunzell DH, Stafford AM, Dixon CI. Nicotinic receptor contributions to smoking: insights from human studies and animal models. Curr Addict Rep  2015; 2(1): 33-46.
[http://dx.doi.org/10.1007/s40429-015-0042-2] [PMID:  26301171] 
[53] 
Morales-Perez CL, Noviello CM, Hibbs RE. X-ray structure of the human α4β2 nicotinic receptor. Nature  2016; 538(7625): 411-5.
[http://dx.doi.org/10.1038/nature19785] [PMID:  27698419] 
[54] 
Lenz RA, Pritchett YL, Berry SM, et al. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord  2015; 29(3): 192-9.
[http://dx.doi.org/10.1097/WAD.0000000000000093] [PMID:  25973909] 
[55] 
Posadas I, López-Hernández B, Ceña V. Nicotinic receptors in neurodegeneration. Curr Neuropharmacol  2013; 11(3): 298-314.
[http://dx.doi.org/10.2174/1570159X11311030005] [PMID:  24179465] 
[56] 
Faundez-Parraguez M, Farias-Rabelo N, Gonzalez-Gutierrez JP, et al. Neonicotinic analogues: selective antagonists for α4β2 nicotinic acetylcholine receptors. Bioorg Med Chem  2013; 21(10): 2687-94.
[http://dx.doi.org/10.1016/j.bmc.2013.03.024] [PMID:  23561269] 
[57] 
Li Y, Sun H, Chen Z, Xu H, Bu G, Zheng H. Implications of GABAergic neurotransmission in Alzheimer’s disease. Front Aging Neurosci  2016; 8: 31.
[http://dx.doi.org/10.3389/fnagi.2016.00031] [PMID:  26941642] 
[58] 
Mandal PK, Kansara K, Dabas A. The GABA-working memory relashionship in Alzheimer´s disease J Alz Dis Rep  2017; 1: 43-5.
[59] 
Grill JD, Cummings JL. Novel targets for Alzheimer’s disease treatment. Expert Ver Neurother  2010; 10: 711-28.
[http://dx.doi.org/10.1586/ern.10.29] 
[60] 
Scimemi A. Structure, function, and plasticity of GABA transportes. Front Cell Neurosci  2014; 8: 1-14.
[http://dx.doi.org/10.3389/fncel.2014.00161] 
[61] 
Drott J, Desire L, Drouin D, Pando M, Haun F. Etazolate improves performance in a foraging and homing task in aged rats. Eur J Pharmacol  2010; 634(1-3): 95-100.
[http://dx.doi.org/10.1016/j.ejphar.2010.02.036] [PMID:  20223232] 
[62] 
Vellas B, Sol O, Snyder PJ, et al. EHT0202/002 study group. EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res  2011; 8(2): 203-12.
[http://dx.doi.org/10.2174/156720511795256053] [PMID:  21222604] 
[63] 
Valproate in Dementia (VALID) ClinicalTrials.gov Identifier: NCT00071721 2020.
[64] 
Tariot PN, Schneider LS, Cummings J, et al. Alzheimer’s Disease Cooperative Study Group. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry  2011; 68(8): 853-61.
[http://dx.doi.org/10.1001/archgenpsychiatry.2011.72] [PMID:  21810649] 
[65] 
Petersen JG, Sørensen T, Damgaard M, et al. Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABA(A) receptor agonists. Eur J Med Chem  2014; 84: 404-16.
[http://dx.doi.org/10.1016/j.ejmech.2014.07.039] [PMID:  25038482] 
[66] 
Claeysen S, Bockaert J, Giannoni P. Serotonin: a new hope in Alzheimer’s disease? ACS Chem Neurosci  2015; 6(7): 940-3.
[http://dx.doi.org/10.1021/acschemneuro.5b00135] [PMID:  26011650] 
[67] 
Butzlaff M, Ponimaskin E. The role of serotoninreceptors in Alzheimer’s disease. Opera Med Physiol  2016; 2: 77-86.
[68] 
Geldenhuys WJ, Van der Schyf CJ. Role of serotonin in Alzheimer’s disease: a new therapeutic target? CNS Drugs  2011; 25(9): 765-81.
[http://dx.doi.org/10.2165/11590190-000000000-00000] [PMID:  21870888] 
[69] 
Jayarajan P, Bhyrapuneni G, Mudigonda K, et al. SUVN-D4010, a potent and selective 5-HT4 receptor partial agonist: safety, tolerability and pharmacokinetics in humans. Alzheimers Dement  2016; 7: 823-4.
[http://dx.doi.org/10.1016/j.jalz.2016.06.1673] 
[70] 
Nirogi R, Mohammed AR, Shinde AK, et al. Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists. J Med Chem  2018; 61(11): 4993-5008.
[http://dx.doi.org/10.1021/acs.jmedchem.8b00457] [PMID:  29763304] 
[71] 
Shen F, Smith JAM, Chang R, et al. 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment. Neuropharmacology  2011; 61(1-2): 69-79.
[http://dx.doi.org/10.1016/j.neuropharm.2011.02.026] [PMID:  21392515] 
[72] 
Sabbagh MN. Drug development for Alzheimer’s disease: where are we now and where are we headed? Am J Geriatr Pharmacother  2009; 7(3): 167-85.
[http://dx.doi.org/10.1016/j.amjopharm.2009.06.003] [PMID:  19616185] 
[73] 
Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol  2010; 9(7): 702-16.
[http://dx.doi.org/10.1016/S1474-4422(10)70119-8] [PMID:  20610346] 
[74] 
Vera G, Lagos CF, Almendras S, et al. Extended N-arylsulfonylindoles as 5-HT6 receptor antagonists: design, synthesis & biological evaluation. Molecules  2016; 21(8): 1-35.
[http://dx.doi.org/10.3390/molecules21081070] [PMID:  27537868] 
[75] 
Gallivan JP, Dougherty DA. Cation-pi interactions in structural biology. Proc Natl Acad Sci USA  1999; 96(17): 9459-64.
[http://dx.doi.org/10.1073/pnas.96.17.9459] [PMID:  10449714] 
[76] 
Mella J, Villegas F, Morales-Verdejo C, Lagos C, Recabarren-Gadajo G. Structure-activity relationships studies on weakly basic N-arylsuldonylindoles with an antagonistic profile in the 5-HT6 receptor. J Mol Struct  2017; 1139: 362-70.
[http://dx.doi.org/10.1016/j.molstruc.2017.03.067] 
[77] 
Naddafi F, Mirshafiey A. The neglected role of histamine in Alzheimer’s disease. Am J Alzheimers Dis Other Demen  2013; 28(4): 327-36.
[http://dx.doi.org/10.1177/1533317513488925] [PMID:  23677734] 
[78] 
Cummings J, Morstorf T, Lee G. Alzheimer’s drug-development pipeline: 2016. Alzheimers Dement (N Y)  2016; 2(4): 222-32.
[http://dx.doi.org/10.1016/j.trci.2016.07.001] [PMID:  29067309] 
[79] 
Vohora D, Bhowmik M. Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer’s disease, ADHD, schizophrenia, and drug abuse. Front Syst Neurosci  2012; 6: 72.
[http://dx.doi.org/10.3389/fnsys.2012.00072] [PMID:  23109919] 
[80] 
Hancock AA. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Biochem Pharmacol  2006; 71(8): 1103-13.
[http://dx.doi.org/10.1016/j.bcp.2005.10.033] [PMID:  16513092] 
[81] 
Haig GM, Pritchett Y, Meier A, et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer’s dementia. J Alzheimers Dis  2014; 42(3): 959-71.
[http://dx.doi.org/10.3233/JAD-140291] [PMID:  25024314] 
[82] 
Wingen K, Stark H. Scaffold variations in amine warhead of histamine H3 receptor antagonists Drug Discov Today. Tech  2013; 10: 483-9.
[83] 
Łazewska D, Kuder K, Ligneau X, et al. Piperidine variations in search for non-imidazole histamine H(3) receptor ligands. Bioorg Med Chem  2008; 16(18): 8729-36.
[http://dx.doi.org/10.1016/j.bmc.2008.07.071] [PMID:  18774720] 
[84] 
García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R. Phosphodiesterases as therapeutic targets for Alzheimer’s disease. ACS Chem Neurosci  2012; 3(11): 832-44.
[http://dx.doi.org/10.1021/cn3000907] [PMID:  23173065] 
[85] 
Heckman PRA, Wouters C, Prickaerts J. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer’s disease: a translational overview. Curr Pharm Des  2015; 21(3): 317-31.
[http://dx.doi.org/10.2174/1381612820666140826114601] [PMID:  25159073] 
[86] 
Ricciarelli R, Fedele E. Phosphodiesterase 4D: an enzyme to remember. Br J Pharmacol  2015; 172(20): 4785-9.
[http://dx.doi.org/10.1111/bph.13257] [PMID:  26211680] 
[87] 
Gallant M, Aspiotis R, Day S, et al. Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. Bioorg Med Chem Lett  2010; 20(22): 6387-93.
[http://dx.doi.org/10.1016/j.bmcl.2010.09.087] [PMID:  20933411] 
[88] 
Prickaerts J, Heckman PRA, Blokland A. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. Expert Opin Investig Drugs  2017; 26(9): 1033-48.
[http://dx.doi.org/10.1080/13543784.2017.1364360] [PMID:  28772081] 
[89] 
Peters M, Bletsch M, Stanley J, Wheeler D, Scott R, Tully T. The PDE4 inhibitor HT-0712 improves hippocampus-dependent memory in aged mice. Neuropsychopharmacology  2014; 39(13): 2938-48.
[http://dx.doi.org/10.1038/npp.2014.154] [PMID:  24964813] 
[90] 
Wang Z, Wang Y, Wang B, Li W, Huang L, Li X. Design, synthesis and evaluation of orally available clioquinol-moracin M hybrids as multi-target-directed ligands for cognitive improvement in a rat model of neurodegeneration in Alzheimer’s disease. J Med Chem  2015; 58(21): 8616-37.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01222] [PMID:  26473791] 
[91] 
Duce JA, Bush AI. Biological metals and Alzheimer’s disease: implications for therapeutics and diagnostics. Prog Neurobiol  2010; 92(1): 1-18.
[http://dx.doi.org/10.1016/j.pneurobio.2010.04.003] [PMID:  20444428] 
[92] 
Ishii M, Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer’s disease: the hypothalamus as both culprit and target of pathology. Cell Metab  2015; 22(5): 761-76.
[http://dx.doi.org/10.1016/j.cmet.2015.08.016] [PMID:  26365177] 
[93] 
Mushtaq G, Khan JA, Kamal MA. Impaired glucose metabolism in Alzheimer’s disease and diabetes Enz Eng  2015; 4: 1-4.
[94] 
Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond)  2009; 6: 31.
[http://dx.doi.org/10.1186/1743-7075-6-31] [PMID:  19664276] 
[95] 
Costantini LC, Barr LJ, Vogel JL, Henderson ST. Hypometabolism as a therapeutic target in Alzheimer'sdisease BMC Nurosc  2008; 9: 1-9.
[96] 
Miller BW, Willett KC, Desilets AR. Rosiglitazone and pioglitazone for the treatment of Alzheimer’s disease. Ann Pharmacother  2011; 45(11): 1416-24.
[http://dx.doi.org/10.1345/aph.1Q238] [PMID:  22028424] 
[97] 
Diniz LP, Tortelli V, Matias I, et al. Astrocyte transforming growth factor beta 1 protects synapses against Aβ oligomers in Alzheimer’s disease model. J Neurosci  2017; 37(28): 6797-809.
[http://dx.doi.org/10.1523/JNEUROSCI.3351-16.2017] [PMID:  28607171] 
[98] 
Schwartz M, Peralta Ramos JM, Ben-Yehuda H. A 20-year journey from axonal injury to neurodegenerative diseases and the prospect of immunotherapy for combating alzheimer’s disease. J Immunol  2020; 204(2): 243-50.
[http://dx.doi.org/10.4049/jimmunol.1900844] [PMID:  31907265] 
[99] 
Liu YH, Zeng F, Wang YR, et al. Immunity and Alzheimer’s disease: immunological perspectives on the development of novel therapies. Drug Discov Today  2013; 18(23-24): 1212-20.
[http://dx.doi.org/10.1016/j.drudis.2013.07.020] [PMID:  23954180] 
[100] 
Jevtic S, Sengar AS, Salter MW, McLaurin J. The role of the immune system in Alzheimer disease: Etiology and treatment. Ageing Res Rev  2017; 40: 84-94.
[http://dx.doi.org/10.1016/j.arr.2017.08.005] [PMID:  28941639] 
[101] 
De Strooper B, Karran E. The cellular phase of Alzheimer’s disease. Cell  2016; 164(4): 603-15.
[http://dx.doi.org/10.1016/j.cell.2015.12.056] [PMID:  26871627] 
[102] 
Su F, Bai F, Zhou H, Zhang Z. Microglial toll-like receptors and Alzheimer’s disease. Brain Behav Immun  2016; 52: 187-98.
[http://dx.doi.org/10.1016/j.bbi.2015.10.010] [PMID: 26526648] 
[103] 
https://investors.biogen.com/news-releases/news-release-details/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease2020
[104] 
Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics. Alzheimers Res Ther  2014; 6(4): 42.
[http://dx.doi.org/10.1186/alzrt272] [PMID:  25045405] 
[105] 
Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature  2016; 537(7618): 50-6.
[http://dx.doi.org/10.1038/nature19323] [PMID:  27582220] 
[106] 
Honig LS, Vellas B, Woodward M, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease. N Engl J Med  2018; 378(4): 321-30.
[http://dx.doi.org/10.1056/NEJMoa1705971] [PMID:  29365294] 
[107] 
https://investor.lilly.com/news-releases/news-release-details/lilly-announces-topline-results-solanezumab-dominantly-inherited2020
[108] 
U.S. Food & Drug Administration Department of Health and Human Services.. https://www.fda.gov/2018
[109] 
Ivleva EA, Klimoichkin YN. Convenient synthesis of memantine hydrochloride. Org Prep Proced Int  2017; 49: 155-62.
[http://dx.doi.org/10.1080/00304948.2017.1291004] 
[110] 
Rawat AS, Pande S, Bhatt N, Kharatkar R, Belwal C, Vardhan A. Synthesis of donepezil hydrochloride via chemoselective hydrogenation. Org Process Res Dev  2013; 10: 1-5.
[http://dx.doi.org/10.1021/op400007p] 
[111] 
Li M, Zheng C, Kawada T, et al. Donepezil markedly improves long-term survival in rats with chronic heart failure after extensive myocardial infarction. Circ J  2013; 77(10): 2519-25.
[http://dx.doi.org/10.1253/circj.CJ-13-0476] [PMID:  23832513] 
[112] 
Foster PS, Drago V, Roosa KM, Campbell RW, Witt JC, Heilman KM. Donepezil versus Rivastigmine in patients with Alzheimer’s disease: attention and working memory. Alz Neurodegener Dis  2016; 2: 1-5.
[http://dx.doi.org/10.24966/AND-9608/100002] 
[113] 
Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer’s disease: an update. Clin Interv Aging  2007; 2(1): 17-32.
[http://dx.doi.org/10.2147/ciia.2007.2.1.17] [PMID:  18044073] 
[114] 
Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditions. Int J Clin Pract  2014; 68(4): 465-70.
[http://dx.doi.org/10.1111/ijcp.12374] [PMID:  24588972] 
[115] 
Yan P, Zhu G, Xie J, et al. Industrial Scale-up of enantioselective hydrogenation for the asymmetric synthesis of Rivastigmine. Org Process Res Dev  2012; 17: 307-12.
[http://dx.doi.org/10.1021/op3003147] 
[116] 
Ng YP, Or TC, Ip NY. Plant alkaloids as drug leads for Alzheimer’s disease. Neurochem Int  2015; 89: 260-70.
[http://dx.doi.org/10.1016/j.neuint.2015.07.018] [PMID:  26220901] 
[117] 
Baakman AC, ’t Hart E, Kay DG, et al. First in human study with a prodrug of galantamine: Improved benefit-risk ratio? Alzheimers Dement (N Y)  2016; 2(1): 13-22.
[http://dx.doi.org/10.1016/j.trci.2015.12.003] [PMID:  29067291] 
[118] 
Marco-Contelles J, do Carmo Carreiras M, Rodríguez C, Villarroya M, García AG. Synthesis and pharmacology of galantamine. Chem Rev  2006; 106(1): 116-33.
[http://dx.doi.org/10.1021/cr040415t] [PMID:  16402773] 
[119] 
Rodrigues Simões MC, Dias Viegas FP, Moreira MS, et al. Donepezil: an important prototype to the design of new drug candidates for Alzheimer’s disease. Mini Rev Med Chem  2014; 14(1): 2-19.
[http://dx.doi.org/10.2174/1389557513666131119201353] [PMID:  24251806] 
[120] 
Silva MF, Dias KST, Gontijo VS, Ortiz CJC, Viegas-Jr C. Recent contributions of the Multi-Target Directed Ligands Approach in the Search for Effective Drugs Towards Alzheimer’s Disease. Curr Med Chem  2018; 12: 2-36.
[121] 
Nesi G, Chen Q, Sestito S, et al. Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer’s disease. Eur J Med Chem  2017; 141: 232-9.
[http://dx.doi.org/10.1016/j.ejmech.2017.10.006] [PMID:  29031070] 
[122] 
Joubert J, Foka GB, Repsold BP, Oliver DW, Kapp E, Malan SF. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer’s disease. Eur J Med Chem  2017; 125: 853-64.
[http://dx.doi.org/10.1016/j.ejmech.2016.09.041] [PMID:  27744252] 
[123] 
Li F, Wu JJ, Wang J, et al. Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer’s disease. Bioorg Med Chem  2017; 25(14): 3815-26.
[http://dx.doi.org/10.1016/j.bmc.2017.05.027] [PMID:  28549891] 
[124] 
Liu Z, Fang L, Zhang H, Gou S, Chen L. Design, synthesis and biological evaluation of multifunctional tacrine-curcumin hybrids as new cholinesterase inhibitors with metal ions-chelating and neuroprotective property. Bioorg Med Chem  2017; 25(8): 2387-98.
[http://dx.doi.org/10.1016/j.bmc.2017.02.049] [PMID:  28302511] 
[125] 
Eghtedari M, Sarrafi Y, Nadri H, et al. New tacrine-derived AChE/BuChE inhibitors: Synthesis and biological evaluation of 5-amino-2-phenyl-4H-pyrano[2,3-b]quinoline-3-carboxylates. Eur J Med Chem  2017; 128: 237-46.
[http://dx.doi.org/10.1016/j.ejmech.2017.01.042] [PMID:  28189905] 
[126] 
Jalili-Baleh L, Nadri H, Moradi A, et al. New racemic annulated pyrazolo[1,2-b]phthalazines as tacrine-like AChE inhibitors with potential use in Alzheimer’s disease. Eur J Med Chem  2017; 139: 280-9.
[http://dx.doi.org/10.1016/j.ejmech.2017.07.072] [PMID:  28803044] 
[127] 
Roldán-Peña JM, Alejandre-Ramos D, López Ó, et al. New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer’s and antiproliferative agents. Eur J Med Chem  2017; 138: 761-73.
[http://dx.doi.org/10.1016/j.ejmech.2017.06.048] [PMID:  28728108] 
[128] 
Gazova Z, Soukup O, Sepsova V, et al. Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer’s disease treatment. Biochim Biophys Acta Mol Basis Dis  2017; 1863(2): 607-19.
[http://dx.doi.org/10.1016/j.bbadis.2016.11.020] [PMID:  27865910] 
[129] 
Yang X, Qiang X, Li Y, et al. Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer’s disease. Bioorg Chem  2017; 71: 305-14.
[http://dx.doi.org/10.1016/j.bioorg.2017.02.016] [PMID:  28267984] 
[130] 
Wang J, Cai P, Yang XL, et al. Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer’s disease. Eur J Med Chem  2017; 139: 68-83.
[http://dx.doi.org/10.1016/j.ejmech.2017.07.077] [PMID:  28800459] 
[131] 
Xu P, Zhang M, Sheng R, Ma Y. Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, Aβ1-42 aggregation inhibitors and metal-chelating agents for Alzheimer’s disease. Eur J Med Chem  2017; 127: 174-86.
[http://dx.doi.org/10.1016/j.ejmech.2016.12.045] [PMID:  28061347] 
[132] 
Reddy EK, Remya C, Mantosh K, et al. Novel tacrine derivatives exhibiting improved acetylcholinesterase inhibition: Design, synthesis and biological evaluation. Eur J Med Chem  2017; 139: 367-77.
[http://dx.doi.org/10.1016/j.ejmech.2017.08.013] [PMID:  28810188] 
[133] 
Lan JS, Liu Y, Hou JW, et al. Design, synthesis and evaluation of resveratrol-indazole hybrids as novel monoamine oxidases inhibitors with amyloid-β aggregation inhibition. Bioorg Chem  2018; 76: 130-9.
[http://dx.doi.org/10.1016/j.bioorg.2017.11.009] [PMID:  29172101] 
[134] 
Xia CL, Wang N, Guo QL, et al. Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer’s disease treatment. Eur J Med Chem  2017; 130: 139-53.
[http://dx.doi.org/10.1016/j.ejmech.2017.02.042] [PMID:  28242549] 
[135] 
Luo L, Li Y, Qiang X, et al. Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer’s disease. Bioorg Med Chem  2017; 25(6): 1997-2009.
[http://dx.doi.org/10.1016/j.bmc.2017.02.027] [PMID:  28237559] 
[136] 
Zhao XJ, Gong DM, Jiang YR, Guo D, Zhu Y, Deng YC. Multipotent AChE and BACE-1 inhibitors for the treatment of Alzheimer’s disease: Design, synthesis and bio-analysis of 7-amino-1,4-dihydro-2H-isoquilin-3-one derivates. Eur J Med Chem  2017; 138: 738-47.
[http://dx.doi.org/10.1016/j.ejmech.2017.07.006] [PMID:  28728106] 
[137] 
Sang Z, Wang K, Wang H, et al. Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett  2017; 27(22): 5053-9.
[http://dx.doi.org/10.1016/j.bmcl.2017.09.055] [PMID:  29033232] 
[138] 
Czarnecka K, Chufarova N, Halczuk K, et al. Tetrahydroacridine derivatives with dichloronicotinic acid moiety as attractive, multipotent agents for Alzheimer’s disease treatment. Eur J Med Chem  2018; 145: 760-9.
[http://dx.doi.org/10.1016/j.ejmech.2018.01.014] [PMID:  29353726] 
[139] 
Xiao G, Li Y, Qiang X, et al. Design, synthesis and biological evaluation of 4′-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg Med Chem  2017; 25(3): 1030-41.
[http://dx.doi.org/10.1016/j.bmc.2016.12.013] [PMID:  28011206] 
[140] 
Palanimuthu D, Poon R, Sahni S, et al. A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer’s disease. Eur J Med Chem  2017; 139: 612-32.
[http://dx.doi.org/10.1016/j.ejmech.2017.08.021] [PMID:  28841514] 
[141] 
Dgachi Y, Sokolov O, Luzet V, et al. Tetrahydropyranodiquinolin-8-amines as new, non hepatotoxic, antioxidant, and acetylcholinesterase inhibitors for Alzheimer’s disease therapy. Eur J Med Chem  2017; 126: 576-89.
[http://dx.doi.org/10.1016/j.ejmech.2016.11.050] [PMID:  27918993] 
[142] 
Li Y, Qiang X, Luo L, et al. Multitarget drug design strategy against Alzheimer’s disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties. Bioorg Med Chem  2017; 25(2): 714-26.
[http://dx.doi.org/10.1016/j.bmc.2016.11.048] [PMID:  27923535] 
[143] 
Ma F, Du H. Novel deoxyvasicinone derivatives as potent multitarget-directed ligands for the treatment of Alzheimer’s disease: Design, synthesis, and biological evaluation. Eur J Med Chem  2017; 140: 118-27.
[http://dx.doi.org/10.1016/j.ejmech.2017.09.008] [PMID:  28923380] 
[144] 
Singh M, Kaur M, Singh N, Silakari O. Exploration of multi-target potential of chromen-4-one based compounds in Alzheimer’s disease: Design, synthesis and biological evaluations. Bioorg Med Chem  2017; 25(24): 6273-85.
[http://dx.doi.org/10.1016/j.bmc.2017.09.012] [PMID:  29089261] 
[145] 
Dias Viegas FP, de Freitas Silva M, Divino da Rocha M, et al. Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates. Eur J Med Chem  2018; 147: 48-65.
[http://dx.doi.org/10.1016/j.ejmech.2018.01.066] [PMID:  29421570] 
[146] 
Xu YX, Wang H, Li XK, et al. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem  2018; 143: 33-47.
[http://dx.doi.org/10.1016/j.ejmech.2017.08.025] [PMID:  29172081] 
[147] 
Qiang X, Li Y, Yang X, et al. DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer’s therapy. Bioorg Med Chem Lett  2017; 27(4): 718-22.
[http://dx.doi.org/10.1016/j.bmcl.2017.01.050] [PMID:  28131710] 
Cite As
Current Drug Targets

Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches

Abstract

Graphical Abstract
